Tags

Type your tag names separated by a space and hit enter

Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration.
Neuroscience. 2011 Aug 11; 188:135-41.N

Abstract

Parkinson's disease is associated with the loss of dopaminergic neurons in the substantia nigra and decreased striatal dopamine levels. We now report that caffeic acid phenethyl ester (CAPE), an active component of propolis, attenuated dopaminergic neurodegeneration and dopamine loss in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease. The neuroprotective effect of CAPE was associated with marked reductions in inducible nitric oxide synthase (iNOS) and caspase 1 expression. Additionally, CAPE inhibited MPP+-induced neurotoxicity in vitro and directly inhibited MPP+-induced release of cytochrome c and apoptosis inducing factor (AIF) from mitochondria. Thus, CAPE may have beneficial effects in slowing or preventing the progression of Parkinson's disease and other neurodegenerative disorders.

Authors+Show Affiliations

Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21571045

Citation

Fontanilla, C V., et al. "Caffeic Acid Phenethyl Ester Prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurodegeneration." Neuroscience, vol. 188, 2011, pp. 135-41.
Fontanilla CV, Ma Z, Wei X, et al. Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration. Neuroscience. 2011;188:135-41.
Fontanilla, C. V., Ma, Z., Wei, X., Klotsche, J., Zhao, L., Wisniowski, P., Dodel, R. C., Farlow, M. R., Oertel, W. H., & Du, Y. (2011). Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration. Neuroscience, 188, 135-41. https://doi.org/10.1016/j.neuroscience.2011.04.009
Fontanilla CV, et al. Caffeic Acid Phenethyl Ester Prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurodegeneration. Neuroscience. 2011 Aug 11;188:135-41. PubMed PMID: 21571045.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration. AU - Fontanilla,C V, AU - Ma,Z, AU - Wei,X, AU - Klotsche,J, AU - Zhao,L, AU - Wisniowski,P, AU - Dodel,R C, AU - Farlow,M R, AU - Oertel,W H, AU - Du,Y, Y1 - 2011/05/06/ PY - 2010/09/13/received PY - 2011/03/30/revised PY - 2011/04/06/accepted PY - 2011/5/17/entrez PY - 2011/5/17/pubmed PY - 2011/10/13/medline SP - 135 EP - 41 JF - Neuroscience JO - Neuroscience VL - 188 N2 - Parkinson's disease is associated with the loss of dopaminergic neurons in the substantia nigra and decreased striatal dopamine levels. We now report that caffeic acid phenethyl ester (CAPE), an active component of propolis, attenuated dopaminergic neurodegeneration and dopamine loss in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease. The neuroprotective effect of CAPE was associated with marked reductions in inducible nitric oxide synthase (iNOS) and caspase 1 expression. Additionally, CAPE inhibited MPP+-induced neurotoxicity in vitro and directly inhibited MPP+-induced release of cytochrome c and apoptosis inducing factor (AIF) from mitochondria. Thus, CAPE may have beneficial effects in slowing or preventing the progression of Parkinson's disease and other neurodegenerative disorders. SN - 1873-7544 UR - https://www.unboundmedicine.com/medline/citation/21571045/Caffeic_acid_phenethyl_ester_prevents_1_methyl_4_phenyl_1236_tetrahydropyridine_induced_neurodegeneration_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0306-4522(11)00389-7 DB - PRIME DP - Unbound Medicine ER -